Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion type Assertion NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_head.
- NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion description "[To improve MRD assessment by MFC, we here evaluate the combination of human Myeloid Inhibitory C-type Lectin (hMICL, also termed C-type lectin domain family 12, member A, CLEC12A) and CD 123 (also termed interleukin-3 receptor alpha, IL3RA) in combination with CD34 and CD117 (KIT), as an MRD assay in pre-clinical and clinical testing in 69 AML patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_provenance.
- NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion evidence source_evidence_literature NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_provenance.
- NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion SIO_000772 24152218 NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_provenance.
- NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion wasDerivedFrom befree-20150227 NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_provenance.
- NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_assertion wasGeneratedBy ECO_0000203 NP977102.RAOwSpg9JmCUf_In3Wcf69XCe_BC53Lvo1K6eRIhBjAUs130_provenance.